Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Bullish +65

Can Eli Lilly’s Growth Keep Justifying its Premium?

Drug pricing Earnings report Guidance raised AI-generated analysis

📈 Eli Lilly stock returned over 55% in the past 12 months, significantly outperforming the S&P 500's 14% growth.

💰 Second-quarter revenue increased 48% year over year to $23.0 billion, driven by a 60% volume increase.

💊 Mounjaro generated $9.9 billion in quarterly revenue (up 91%), while Zepbound contributed $4.9 billion (up 44%).

📈 Non-GAAP earnings per rose 33% to $8.38, supported by a gross margin improvement to 86.3%.

🏭 Lilly committed an additional $4.5 billion to expand manufacturing capacity in Indiana to meet rising demand.

💊 Foundayo, the oral GLP-1 medicine, generated $98 million in second-quarter revenue.

🔬 Investigational obesity treatment retatrutide delivered positive Phase 3 results with an FDA submission planned for early 2027.

📉 International revenue increased 80% but faced a 36% decline in realized prices due to reimbursement pressures in China.

💸 Acquisition-related R&D charges of $3.03 per share offset the management's underlying EPS outlook increase of $2.78.

⚖️ The article questions whether Lilly can maintain earnings momentum to justify its premium valuation as sales expand.

Bullish Signals
  • Eli Lilly stock returned over 55% in the past 12 months, significantly outperforming the S&P 500's 14% growth.
  • Second-quarter revenue surged 48% year over year to $23.0 billion, driven by a robust 60% increase in volume.
  • Non-GAAP earnings per share rose 33% to $8.38, demonstrating strong profitability growth.
  • Gross margins improved to 86.3%, up 1.3 percentage points, supported by better production costs and product mix.
  • Management raised full-year revenue guidance to $85 billion–$87 billion from the previous $82 billion–$85 billion range.
  • Lilly committed an additional $4.5 billion to expand manufacturing capacity in Indiana to sustain growth.
  • Foundayo, the oral GLP-1 medicine, generated $98 million in second-quarter revenue, diversifying the franchise.
  • Investigational obesity treatment retatrutide delivered positive Phase 3 results with an FDA submission planned for early 2027.
Risk Factors
  • Realized prices declined by 13% domestically and 36% internationally, partially offsetting volume growth.
  • International revenue faced significant pricing pressure, attributed to Mounjaro's inclusion on China's National Reimbursement Drug List.
  • Acquisition-related research and development charges of $3.03 per share more than offset the increase in underlying EPS outlook.
Full Analysis
Eli Lilly and Company (NYSE:LLY) has delivered exceptional growth, with its stock returning over 55% in the past year compared to a 14% gain for the S&P 500. This premium valuation is driven by substantial expectations for future profitability, particularly from its diabetes and obesity treatments, Mounjaro and Zepbound, which are driving extraordinary sales momentum. Second-quarter results provided strong support for these growth expectations, with revenue surging 48% year over year to $23.0 billion, fueled by a 60% increase in volume. Non-GAAP earnings per share rose 33% to $8.38, while Mounjaro generated $9.9 billion and Zepbound contributed $4.9 billion in quarterly revenue. Together, these two medicines accounted for a significant portion of the company's total revenue. Profitability improvements further bolstered investor confidence, with non-GAAP gross margins expanding to 86.3%. To sustain this momentum, Lilly committed an additional $4.5 billion to expand manufacturing capacity in Indiana. The company is also advancing its pipeline, including oral GLP-1 medicine Foundayo and investigational treatment retatrutide, which showed positive Phase 3 results. However, the article highlights key risks regarding the sustainability of this growth. While volume growth has compensated for declining realized prices domestically, international revenue faced significant pricing pressure due to factors like Mounjaro's inclusion on China's National Reimbursement Drug List. Management raised underlying full-year non-GAAP EPS outlook by $2.78 at the midpoint, but acquisition-related R&D charges of $3.03 per share offset this in published guidance.